EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 24 / No 5 (Mai 2008) Med Sci (Paris), 24 5 (2008) 511-520 References
Free Access
Issue
Med Sci (Paris)
Volume 24, Number 5, Mai 2008
Page(s) 511 - 520
Section M/S revues
DOI https://doi.org/10.1051/medsci/2008245511
Published online 15 May 2008
  1. Smeds AI, Eklund PC, Sjöholm RE, et al. Quantification of a broad spectrum of lignans in cereals, oilseeds, and nuts. J Agric Food Chem 2007; 55 : 1337–46. [Google Scholar]
  2. Hall C III, Tulbek M, Xu, Y. Flaxseed. Adv Food Nutr Res 2006; 51 : 1–97. [Google Scholar]
  3. Lainé E, Hano C, Lamblin F. Les lignanes phyto-œstrogènes du lin sont ils des bienfaiteurs méconnus ? Phytothérapie 2007; 5 : 121–8. [Google Scholar]
  4. Cho JY, Kim AR, Yoo ES, et al. Immunomodulatory effect of arctigenin, a lignan compound, on tumour necrosis factor-a and nitric oxide production and lymphocyte proliferation. J Pharm Pharmacol 1999; 51 : 1267–73. [Google Scholar]
  5. Adlercreutz H. Phyto-œstrogens and cancer. Lancet Oncology 2002; 6 : 364–73. [Google Scholar]
  6. Adlercreutz H, Bannwart C, Wahala K, et al. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J Steroid Biochem Mol Biol 1993; 44 : 147–53. [Google Scholar]
  7. Brooks JD, Thompson LU. Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells. J Steroid Biochem Mol Biol 2005; 94 : 461–7. [Google Scholar]
  8. Martin ME, Haourigui M, Pelissero C, et al. Interactions between phytœstrogens and human sex steroid binding protein. Life Sci 1996; 58 : 429–36. [Google Scholar]
  9. Schottner M, Spiteller G. Lignans interfering with 5alpha-dihydrotestosterone binding to human sex hormone-binding globulin. J Nat Prod 1998; 61 : 119–21. [Google Scholar]
  10. Li D, Yee JA, Thompson LU, Yan L. Dietary supplementation with secoisolariciresinol diglycoside (SDG) reduces experimental metastasis of melanoma cells in mice. Cancer Lett 1999; 142 : 91–6. [Google Scholar]
  11. Bylund A, Saarinen N, Zhang JX, et al. Anticancer effects of a plant lignan 7-hydroxymatairesinol on a prostate cancer model in vivo. Exp Biol Med (Maywood) 2005; 230 : 217–23. [Google Scholar]
  12. Thompson LU, Chen JM, Li T, et al. Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. Clin Cancer Res 2005; 11 : 3828–35. [Google Scholar]
  13. Danbara N, Yuri T, Tsujita-Kyutoku M, et al. Enterolactone induces apoptosis and inhibits growth of Colo 201 human colon cancer cells both in vitro and in vivo. Anticancer Res 2005; 25 : 2269–76. [Google Scholar]
  14. Magee PJ, McGlynn H, Rowland. Differential effects of isoflavones and lignans on invasiveness of MDA-MB-231 breast cancer cells in vitro. Cancer Lett 2004; 208 : 35–41. [Google Scholar]
  15. Chen J, Thompson LU. Lignans and tamoxifen, alone or in combination, reduce human breast cancer cell adhesion, invasion, and migration in vitro. Br Can Res Treat 2003; 80 : 163–70. [Google Scholar]
  16. Bergman Jungestrom M, Thompson LU, Dabrosin C. Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. Clin Cancer Res 2007; 13 : 1061–7. [Google Scholar]
  17. Prasad K. Hydroxyl radical-scavenging property of secoisolariciresinol diglucoside (SDG) isolated from flax-seed. Mol Cell Biochem 1997; 168 : 117–23. [Google Scholar]
  18. Kitts DD, Yuan YV, Wijewickreme AN, Thompson LU. Antioxidant activity of the flaxseed lignan secoisolariciresinol diglycoside and its mammalian lignan metabolites enterodiol and enterolactone. Mol Cell Biochem 1999; 202 : 91–100. [Google Scholar]
  19. Imbert F. Discovery of podophyllotoxin. Biochimie 1998; 80 : 207–22. [Google Scholar]
  20. Canel C, Moraes RM, Dayan FE, Ferreira D. Podophyllotoxin. Phytochemistry 2000; 54 : 115–20. [Google Scholar]
  21. El Maalouf G, Rodier JM, Faivre S, Raymond E. Could we expect to improve survival in small cell lung cancer ? Lung Cancer 2007; 57 : 30–4. [Google Scholar]
  22. Lally BE, Urbanic JJ, Blackstock AW, et al. Small cell lung cancer : have we made any progress over the last 25 years ? The Oncologist 2007; 12 : 1096–104. [Google Scholar]
  23. Sung PA, Libura J, Richardson C. Etoposide and illegitimate DNA double-strand break repair in the generation of MLL translocations : new insights and new questions. DNA Repair 2006; 5 : 1109–18. [Google Scholar]
  24. Guenfoudi-Roullaud MP, Menat C, Girard F, et al. Etoposide et risque leucémogène. J Pharm Clin 1998; 17 : 71–3. [Google Scholar]
  25. Schacter L. Etoposide phosphate : what, why, where, and how ? Semin Oncol 1996; 23 : 1–7. [Google Scholar]
  26. Hande K. Topoisomerase II inhibitors. Update Cancer Ther 2006; 1 : 3–15. [Google Scholar]
  27. Champoux JJ. DNA topoisomerases : structure, function, and mechanism. Annu Rev Biochem 2001; 70 : 369–413. [Google Scholar]
  28. Wang JC. Cellular roles of DNA topoisomerases : a molecular perspective. Nat Rev Mol Cell Biol 2002; 3 : 430–40. [Google Scholar]
  29. Azarova AM, Lyu YL, Lin CP, et al. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci USA 2007; 104 : 11014–9. [Google Scholar]
  30. Leroy D, Kajava AV, Frei C, Gasser SM. Analysis of etoposide binding to subdomains of human DNA topoisomerase II alpha in the absence of DNA. Biochemistry 2001; 40 : 1624–34. [Google Scholar]
  31. Montecucco A, Biamonti G. Cellular response to etoposide treatment. Cancer Lett 2007; 252 : 9–18. [Google Scholar]
  32. Cosse JP, Sermeus A, Vannuvel K, et al. Differential effects of hypoxia on etoposide induced apoptosis according to the cancer lines. Mol Cancer 2007; 6 : 61. [Google Scholar]
  33. Clifford B, Beljin M, Stark GR, Taylor WR. G2 arrest in response to topoisomerase II inhibitors the Role of p53. Cancer Res 2003; 63 : 4074–81. [Google Scholar]
  34. Bjørling-Poulsen M, Issinger OG. CDNA array analysis of alterations in gene expression in the promyelocytic leukemia cell line, HL-60, after apoptosis induction with etoposide. Apoptosis 2003; 8 : 377–88. [Google Scholar]
  35. Okada Y, Tosaka A, Nimura Y, et al. Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II alpha. Gene 2001; 272 : 141–8. [Google Scholar]
  36. Gillet JP, Efferth T, Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 2007; 1775 : 237–62. [Google Scholar]
  37. Castro MA, Miguel del Corral JM, Gordaliza M, et al. Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin J Med Chem 2004; 47 : 1214–22. [Google Scholar]
  38. Magedov IV, Manpadi M, Van Slambrouck S, et al. Discovery and investigation of antiproliferative and apoptosis-inducing properties of new heterocyclic podophyllotoxin analogues accessible by a one-step multicomponent synthesis. J Med Chem 2007; 50 : 5183–92. [Google Scholar]
  39. Wiltermann AM, Bender RP, Godfrey M, et al. Topoisomerase II-drug inteaction domains : identification of substituents on etoposide that interact with the enzyme. Biochemistry 2007; 46 : 8217–25. [Google Scholar]
  40. Zhang FM, Yao XJ, Tu YQ. Synthesis and biological evaluation of new 4β-5-Fu-substituted 4’-demethylepipodophyllotoxin derivatives. Molecules 2006; 11 : 849–57. [Google Scholar]
  41. Medarde M, Ramos AC, Caballero E, et al. A New approach to the synthesis of podophyllotoxin based on epimerization reactions. Tetrahedron Lett 1996; 37 : 2663–66. [Google Scholar]
  42. Farkya S, Bisaria VS, Srivastava AK. Biotechnological aspects of the production of the anticancer drug podophyllotoxin. Appl Microbiol Biotechnol 2004; 65 : 504–19 [Google Scholar]
  43. Gordaliza M, García PA, Miguel del Corral JM, Castro MA, Gómez-Zurita MA. Podophyllotoxin : distribution, sources, applications and new cytotoxic derivatives Toxicon 2004; 44 : 441–59 [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.